Clinical Trials

ILCOR guidelines recommend Target Temperature Management (TTM) to between 32°C and 36°C after out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial, TTM at 33°C did not confer a survival benefit or improved neurological function, compared to TTM at 36°C. A lower target temperature might be beneficial compared with normothermia and early treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study any differences in mortality, neurological function and quality of life between a target temperature of 33°C and standard care avoiding fever.

This study is an observational study to determine predictors of sudden cardiac death or appropriate ICD therapy in patients with non-ischemic cardiomyopathy. Patients will be followed for 36 months for the occurrence of sudden cardiac death

This purpose of this study is to evaluate the feasibility and safety of dobutamine stress echocardiography in patients who suffered an OHCA, as a way to predict recovery of heart function.

This study is designed to identify genes shared between humans with hypertrophic cardiomyopathy and rhesus macaque primates who have experienced sudden cardiac death.

The primary purpose/objective of this study is to determine whether myectomy as a management option for severe hypertrophic cardiomyopathy (HCM) reduces the incidence of sudden cardiac death.

The aim of this study is to identify genes shared between humans and rhesus macaque primates who have been diagnosed with hypertrophic cardiomyopathy and have died suddenly.

The purpose of this study is to evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients. This is a single arm prospective study with 30 patients eligible for implantation of an ICD for the secondary prevention of sudden cardiac death.

Spontaneous coronary artery dissection (SCAD) is uncommon but important cause of acute coronary syndrome and sudden cardiac death. There is very little data exists in regards to patient clinical characteristics, risk factors, treatment and outcomes. Our objective is to prospectively assess long term outcomes.